Handelsbanken Fonder AB Grows Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Handelsbanken Fonder AB grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 22.7% in the second quarter, HoldingsChannel.com reports. The firm owned 152,064 shares of the medical equipment provider’s stock after acquiring an additional 28,130 shares during the period. Handelsbanken Fonder AB’s holdings in Zimmer Biomet were worth $13,091,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ZBH. PNC Financial Services Group Inc. lifted its position in shares of Zimmer Biomet by 9.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock valued at $14,495,000 after acquiring an additional 13,883 shares in the last quarter. Morningstar Investment Management LLC boosted its stake in Zimmer Biomet by 235.4% in the 4th quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider’s stock worth $5,204,000 after purchasing an additional 40,610 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in Zimmer Biomet by 257.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider’s stock worth $3,091,000 after purchasing an additional 24,748 shares during the period. Robertson Stephens Wealth Management LLC purchased a new stake in Zimmer Biomet during the 4th quarter valued at approximately $1,131,000. Finally, CIBC Asset Management Inc raised its position in shares of Zimmer Biomet by 67.6% during the fourth quarter. CIBC Asset Management Inc now owns 46,516 shares of the medical equipment provider’s stock valued at $4,183,000 after buying an additional 18,769 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Insider Activity

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares in the company, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.28% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have issued reports on ZBH shares. Zacks Research downgraded shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a report on Monday, July 27th. Barclays decreased their target price on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a research report on Wednesday, April 29th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. JPMorgan Chase & Co. cut their target price on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. Finally, Sanford C. Bernstein boosted their price target on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $104.42.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $99.47 on Friday. The business’s 50 day moving average price is $91.24 and its 200-day moving average price is $90.47. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $108.29. The company has a market cap of $18.97 billion, a P/E ratio of 24.20, a P/E/G ratio of 3.11 and a beta of 0.45. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same period in the previous year, the firm earned $2.07 earnings per share. Zimmer Biomet’s quarterly revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.53 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Investors of record on Thursday, June 25th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend was Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is 23.36%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.